Brief: Theranexus And The BBDF Foundation Finalize Enrollment For The Phase I/II Study Evaluating Batten-1 In Batten Disease
08/09/2022 17:22
Sept 8 (Reuters) - Theranexus SA ALTHX.PA :
* THERANEXUS AND THE BBDF FOUNDATION FINALIZE ENROLLMENT FOR
THE
PHASE I/II STUDY EVALUATING BATTEN-1 IN BATTEN DISEASE
Source text for Eikon: ID:nACT76153
Further company coverage: ALTHX.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Thx Pharma SA
See all newsBrief: Theranexus And BBDF Announce Final And Positive Safety And Efficacy Data In The Phase I/II Trial Testing Batten-1
Brief: Theranexus End-Dec Total Available Funds Stood At EUR 4.9 Mln
Brief: Theranexus Declares Encouraging Prelim Results For Batten Disease Drug
Brief: Theranexus And BBDF Granted Positive Opinion By EMA For Design Of Batten-1 Phase III Trial
Brief: Theranexus And BBDF Win FDA Approval On Endpoints For Phase III Trial To Evaluate Batten-1 In CLN3 Batten Disease